Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vicriviroc - Merck & Co.

Drug Profile

Vicriviroc - Merck & Co.

Alternative Names: MK-7690; SCH-417; SCH-417690; SCH-D; Schering-D

Latest Information Update: 20 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Schering-Plough
  • Developer Merck & Co
  • Class Antineoplastics; Antiretrovirals; Piperazines; Pyrimidines
  • Mechanism of Action CCR5 receptor antagonists; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer
  • Discontinued HIV-1 infections

Most Recent Events

  • 12 Sep 2019 Merck withdraws the phase III VICTOR-E2 trial in HIV-1 infections (Combination therapy, Treatment experienced) prior to enrolment (NCT00243568)
  • 24 Sep 2018 Phase-II clinical trials in Colorectal cancer (Combination therapy, Second-line therapy or greater, Late-stage disease, Metastatic disease) in USA (PO)
  • 15 Aug 2018 Merck Sharp & Dohme plans a phase II trial for Colorectal cancer (Second-line therapy or greater; Late-stage disease) in September 2018 , (NCT03631407)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top